News | January 31, 2014

UPMC Treats Cancer Patients with CyberKnife System

Accuray CyberKnife M6 Radiation Oncology Radiosurgery System UPMC
January 31, 2014 — UPMC CancerCenter radiation oncologists have begun to treat cancer patients with the newest generation CyberKnife System. The radiosurgery system enables physicians to more precisely shape radiation beams to tumors, maximize dose delivered while maintaining health of surrounding tissue intact and decrease length of treatments. UPMC CancerCenter performs about 550 cases a year with the CyberKnife System.
The newest-generation CyberKnife System, known as the M6, is being used at the Mary Hillman Jennings Radiation Oncology Center at UPMC Shadyside and is one of five currently in use in the United States. The first patient at UPMC treated using the CyberKnife M6 System in October 2013 experienced a 50 percent reduction in treatment time. About 80 patients have been treated so far using the new system.
Treatment with the M6 is typically completed in one to five days and requires no anesthesia or recovery time. The system also can track for tumor movement and automatically correct for motion throughout treatment so patients don’t need to be repositioned on the treatment table.
“We are excited to be able to offer patients in western Pennsylvania the most advanced cancer treatment options available,” said Dwight E. Heron, M.D., director of Radiation Services, UPMC CancerCenter, and vice chairman of radiation oncology at the University of Pittsburgh Cancer Institute. “The new CyberKnife System is another tool we have that can ensure we are delivering the most precise, personalized and best treatment available.”
Accuray Inc.’s CyberKnife M6 System has an Iris Collimator to allow radiation delivery in different sized beams from each treatment position without harming surrounding healthy tissue. Along with the device’s robotic arm, this feature enables eligibility for more patients with difficult-to-treat tumors. UPMC plans to implement the multileaf collimator on the Cyberknife M6 System to allow for even more precise delivery of radiation by shaping radiation to the form of the tumor.
For more information:

Related Content

more healthcare providers and patients are choosing options such as Gamma Knife stereotactic radiosurgery
News | Radiation Therapy | July 31, 2017
Each year, up to 650,000 people who were previously diagnosed with various forms of cancer will develop brain...
Elekta’s MR-linac integrates an advanced linear accelerator and a 1.5T magnetic resonance imaging (MRI) system

Elekta’s MR-linac integrates an advanced linear accelerator and a 1.5T magnetic resonance imaging (MRI) system. Combined, these systems will allow for simultaneous radiation therapy delivery and high-field MR tumor monitoring.

Feature | Radiation Oncology | July 05, 2017 | By Jeff Zagoudis
Image-guided radiation therapy offers great potential to improve the efficiency of treating cancer patients by more...

Photo courtesy of RaySearch

Feature | Treatment Planning | July 05, 2017 | By Jeff Zagoudis
While radiation oncologists have a number of proven techniques at their disposal for treating patients, the reality is...
Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...

Image courtesy of Elekta

News | Radiation Therapy | June 13, 2017
Radiation therapy (RT) using high-energy particles, like X-rays or electron beams, is a common and critical component...
News | Radiation Oncology | June 12, 2017
The alliance will study the feasibility of using CRnR’s converging x-ray lens technology as an effective radiotherapy...
stereotactic body radiation therapy (SBRT)
News | Stereotactic Body Radiation Therapy (SBRT) | June 12, 2017
The American Society for Radiation Oncology (ASTRO) issued a new clinical guideline for the use of stereotactic body...
Sponsored Content | Case Study | Radiation Therapy | June 08, 2017
Stereotactic body radiation therapy (SBRT) employs significantly higher per fraction radiation doses than conventional...
pediatric imaging
News | Radiation Oncology | June 08, 2017
In an article published in the June 2017 issue of The Journal of Nuclear Medicine, researchers assert that e
Feature | Radiation Therapy | June 07, 2017 | By Melinda Taschetta-Millane
According to the National Institutes of Health (NIH), precision-based medicine is an emerging approach for disease tr
Overlay Init